drug · small molecule

ibrutinib

Marketedupdated 5mo ago

by $ABBV AbbVie Inc.🔗 ChEMBL

Approved

annual revenue · 2024–2024peak $3.5B

community read0 votes

🐶 often sniffed alongside

top 2

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 40 investigational indications.

targets

Tyrosine-protein kinase BTK

all catalysts(0)

nothing on the calendar yet

Trials studying ibrutinib

phase3A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)recruitingn=180
phase3A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)active not recruitingn=211
phase3A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravisactive not recruitingn=180
—Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemiarecruitingn=180
phase3Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)active not recruitingn=500
phase2Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphomaactive not recruitingn=129
phase3A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)recruitingn=1,200
phase3Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeksnot yet recruitingn=382

Patent cliff

source: FDA Orange Book

first barrier falls

Dec 28, 2026

90 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (448)

Jun 14, 2039formulationUS 12201690
Sep 3, 2036patentUS 10010507*PED
Sep 3, 2036patentUS 10010507*PED
Sep 3, 2036patentUS 10010507*PED
Sep 3, 2036patentUS 10010507*PED
Sep 3, 2036patentUS 10213386*PED
Sep 3, 2036patentUS 10213386*PED
Sep 3, 2036patentUS 10213386*PED
Sep 3, 2036patentUS 10213386*PED
Sep 3, 2036patentUS 10828259*PED
Sep 3, 2036patentUS 10828259*PED
Sep 3, 2036patentUS 10828259*PED
Sep 3, 2036patentUS 10828259*PED
Sep 3, 2036patentUS 9655857*PED
Sep 3, 2036patentUS 9655857*PED
Sep 3, 2036patentUS 9655857*PED
Sep 3, 2036patentUS 9655857*PED
Apr 6, 2036formulationUS 12364698
Mar 3, 2036formulationUS 10010507
Mar 3, 2036formulationUS 10010507
Mar 3, 2036formulationUS 10010507
Mar 3, 2036formulationUS 10010507
Mar 3, 2036formulationUS 10213386
Mar 3, 2036formulationUS 10213386
Mar 3, 2036formulationUS 10213386
Mar 3, 2036formulationUS 10213386
Mar 3, 2036formulationUS 10828259
Mar 3, 2036formulationUS 10828259
Mar 3, 2036formulationUS 10828259
Mar 3, 2036formulationUS 10828259
Mar 3, 2036formulationUS 12551448
Mar 3, 2036formulationUS 12551448
Mar 3, 2036formulationUS 12551448
Mar 3, 2036formulationUS 9655857
Mar 3, 2036formulationUS 9655857
Mar 3, 2036formulationUS 9655857
Mar 3, 2036formulationUS 9655857
Apr 24, 2035patentUS 10463668*PED
Apr 24, 2035patentUS 10463668*PED
Apr 24, 2035patentUS 10463668*PED
Apr 24, 2035patentUS 10463668*PED
Apr 24, 2035patentUS 10463668*PED
Apr 24, 2035patentUS 10463668*PED
Apr 24, 2035patentUS 10695350*PED
Apr 24, 2035patentUS 10695350*PED
Apr 24, 2035patentUS 10695350*PED
Apr 24, 2035patentUS 10695350*PED
Apr 24, 2035patentUS 10695350*PED
Apr 24, 2035patentUS 10695350*PED
Apr 24, 2035patentUS 9795604*PED
Apr 24, 2035patentUS 9795604*PED
Apr 24, 2035patentUS 9795604*PED
Apr 24, 2035patentUS 9795604*PED
Apr 24, 2035patentUS 9795604*PED
Apr 24, 2035patentUS 9795604*PED
Apr 24, 2035patentUS 9795604*PED
Oct 24, 2034method-of-use (U-2654)US 10463668
Oct 24, 2034method-of-use (U-2654)US 10463668
Oct 24, 2034method-of-use (U-2654)US 10463668
Oct 24, 2034method-of-use (U-2654)US 10463668
Oct 24, 2034method-of-use (U-2654)US 10463668
Oct 24, 2034method-of-use (U-2654)US 10463668
Oct 24, 2034method-of-use (U-2970)US 10463668
Oct 24, 2034method-of-use (U-2846)US 10695350
Oct 24, 2034method-of-use (U-2970)US 10695350
Oct 24, 2034method-of-use (U-2846)US 10695350
Oct 24, 2034method-of-use (U-2846)US 10695350
Oct 24, 2034method-of-use (U-2846)US 10695350
Oct 24, 2034method-of-use (U-2846)US 10695350
Oct 24, 2034method-of-use (U-2846)US 10695350
Oct 24, 2034method-of-use (U-2969)US 9795604
Oct 24, 2034method-of-use (U-2969)US 9795604
Oct 24, 2034method-of-use (U-2970)US 9795604
Oct 24, 2034method-of-use (U-2970)US 9795604
Oct 24, 2034method-of-use (U-2970)US 9795604
Oct 24, 2034method-of-use (U-2969)US 9795604
Oct 24, 2034method-of-use (U-2969)US 9795604
Apr 30, 2034patentUS 9296753*PED
Apr 30, 2034patentUS 9296753*PED
Apr 30, 2034patentUS 9296753*PED
Apr 30, 2034patentUS 9296753*PED
Apr 30, 2034patentUS 9296753*PED
Apr 30, 2034patentUS 9296753*PED
Apr 30, 2034patentUS 9296753*PED
Feb 18, 2034patentUS 9540382*PED
Feb 18, 2034patentUS 9540382*PED
Dec 3, 2033patentUS 10106548*PED
Dec 3, 2033patentUS 10106548*PED
Dec 3, 2033patentUS 10106548*PED
Dec 3, 2033patentUS 10106548*PED
Dec 3, 2033patentUS 10106548*PED
Dec 3, 2033patentUS 10106548*PED
Dec 3, 2033patentUS 10106548*PED
Dec 3, 2033patentUS 10125140*PED
Dec 3, 2033patentUS 10125140*PED
Dec 3, 2033patentUS 10125140*PED
Dec 3, 2033patentUS 10125140*PED
Dec 3, 2033patentUS 10125140*PED
Dec 3, 2033patentUS 10125140*PED
Dec 3, 2033patentUS 10125140*PED
Dec 3, 2033patentUS 10294231*PED
Dec 3, 2033patentUS 10294231*PED
Dec 3, 2033patentUS 10294232*PED
Dec 3, 2033patentUS 10294232*PED
Dec 3, 2033patentUS 10752634*PED
Dec 3, 2033patentUS 10752634*PED
Dec 3, 2033patentUS 10961251*PED
Dec 3, 2033patentUS 10961251*PED
Dec 3, 2033patentUS 10961251*PED
Dec 3, 2033patentUS 10961251*PED
Dec 3, 2033patentUS 10961251*PED
Dec 3, 2033patentUS 10961251*PED
Dec 3, 2033patentUS 10961251*PED
Dec 3, 2033patentUS 9713617*PED
Dec 3, 2033patentUS 9713617*PED
Dec 3, 2033patentUS 9725455*PED
Dec 3, 2033patentUS 9725455*PED
Dec 3, 2033patentUS 9725455*PED
Dec 3, 2033patentUS 9725455*PED
Dec 3, 2033patentUS 9725455*PED
Dec 3, 2033patentUS 9725455*PED
Dec 3, 2033patentUS 9725455*PED
Oct 30, 2033compositionUS 9296753
Oct 30, 2033compositionUS 9296753
Oct 30, 2033compositionUS 9296753
Oct 30, 2033compositionUS 9296753
Oct 30, 2033compositionUS 9296753
Oct 30, 2033compositionUS 9296753
Oct 30, 2033compositionUS 9296753
Aug 18, 2033method-of-use (U-1650)US 9540382
Aug 18, 2033method-of-use (U-1684)US 9540382
Jun 3, 2033compositionUS 10106548
Jun 3, 2033compositionUS 10106548
Jun 3, 2033compositionUS 10106548
Jun 3, 2033compositionUS 10106548
Jun 3, 2033compositionUS 10106548
Jun 3, 2033compositionUS 10106548
Jun 3, 2033compositionUS 10106548
Jun 3, 2033compositionUS 10125140
Jun 3, 2033compositionUS 10125140
Jun 3, 2033compositionUS 10125140
Jun 3, 2033compositionUS 10125140
Jun 3, 2033compositionUS 10125140
Jun 3, 2033compositionUS 10125140
Jun 3, 2033compositionUS 10125140
Jun 3, 2033formulationUS 10294231
Jun 3, 2033formulationUS 10294231
Jun 3, 2033formulationUS 10294232
Jun 3, 2033formulationUS 10294232
Jun 3, 2033formulationUS 10752634
Jun 3, 2033formulationUS 10752634
Jun 3, 2033formulationUS 10961251
Jun 3, 2033formulationUS 10961251
Jun 3, 2033formulationUS 10961251
Jun 3, 2033formulationUS 10961251
Jun 3, 2033formulationUS 10961251
Jun 3, 2033formulationUS 10961251
Jun 3, 2033formulationUS 10961251
Jun 3, 2033formulationUS 9713617
Jun 3, 2033formulationUS 9713617
Jun 3, 2033compositionUS 9725455
Jun 3, 2033compositionUS 9725455
Jun 3, 2033compositionUS 9725455
Jun 3, 2033compositionUS 9725455
Jun 3, 2033compositionUS 9725455
Jun 3, 2033compositionUS 9725455
Jun 3, 2033compositionUS 9725455
Dec 3, 2031patentUS 10004746*PED
Dec 3, 2031patentUS 10004746*PED
Dec 3, 2031patentUS 10004746*PED
Dec 3, 2031patentUS 10004746*PED
Dec 3, 2031patentUS 10004746*PED
Dec 3, 2031patentUS 10004746*PED
Dec 3, 2031patentUS 10016435*PED
Dec 3, 2031patentUS 10016435*PED
Dec 3, 2031patentUS 10016435*PED
Dec 3, 2031patentUS 10016435*PED
Dec 3, 2031patentUS 10016435*PED
Dec 3, 2031patentUS 10016435*PED
Dec 3, 2031patentUS 10478439*PED
Dec 3, 2031patentUS 10478439*PED
Dec 3, 2031patentUS 10478439*PED
Dec 3, 2031patentUS 10478439*PED
Dec 3, 2031patentUS 10478439*PED
Dec 3, 2031patentUS 10478439*PED
Dec 3, 2031patentUS 10478439*PED
Dec 3, 2031patentUS 10653696*PED
Dec 3, 2031patentUS 10751342*PED
Dec 3, 2031patentUS 10751342*PED
Dec 3, 2031patentUS 10751342*PED
Dec 3, 2031patentUS 10751342*PED
Dec 3, 2031patentUS 10751342*PED
Dec 3, 2031patentUS 10751342*PED
Dec 3, 2031patentUS 8754090*PED
Dec 3, 2031patentUS 8999999*PED
Dec 3, 2031patentUS 8999999*PED
Dec 3, 2031patentUS 8999999*PED
Dec 3, 2031patentUS 8999999*PED
Dec 3, 2031patentUS 8999999*PED
Dec 3, 2031patentUS 8999999*PED
Dec 3, 2031patentUS 9125889*PED
Dec 3, 2031patentUS 9125889*PED
Dec 3, 2031patentUS 9125889*PED
Dec 3, 2031patentUS 9125889*PED
Dec 3, 2031patentUS 9125889*PED
Dec 3, 2031patentUS 9125889*PED
Dec 3, 2031patentUS 9801881*PED
Dec 3, 2031patentUS 9801881*PED
Dec 3, 2031patentUS 9801881*PED
Dec 3, 2031patentUS 9801881*PED
Dec 3, 2031patentUS 9801881*PED
Dec 3, 2031patentUS 9801881*PED
Dec 3, 2031patentUS 9801883*PED
Dec 3, 2031patentUS 9801883*PED
Dec 3, 2031patentUS 9801883*PED
Dec 3, 2031patentUS 9801883*PED
Dec 3, 2031patentUS 9801883*PED
Dec 3, 2031patentUS 9801883*PED
Dec 3, 2031patentUS 9814721*PED
Jun 3, 2031method-of-use (U-2241)US 100047464.7y
Jun 3, 2031method-of-use (U-3847)US 100047464.7y
Jun 3, 2031method-of-use (U-2242)US 100047464.7y
Jun 3, 2031method-of-use (U-2242)US 100047464.7y
Jun 3, 2031method-of-use (U-1684)US 100047464.7y
Jun 3, 2031method-of-use (U-1946)US 100047464.7y
Jun 3, 2031method-of-use (U-2241)US 100047464.7y
Jun 3, 2031method-of-use (U-1650)US 100164354.7y
Jun 3, 2031method-of-use (U-1650)US 100164354.7y
Jun 3, 2031method-of-use (U-1650)US 100164354.7y
Jun 3, 2031method-of-use (U-1650)US 100164354.7y
Jun 3, 2031method-of-use (U-3845)US 100164354.7y
Jun 3, 2031method-of-use (U-1650)US 100164354.7y
Jun 3, 2031method-of-use (U-1650)US 100164354.7y
Jun 3, 2031method-of-use (U-3422)US 104784394.7y
Jun 3, 2031method-of-use (U-3845)US 104784394.7y
Jun 3, 2031method-of-use (U-3422)US 104784394.7y
Jun 3, 2031method-of-use (U-3422)US 104784394.7y
Jun 3, 2031method-of-use (U-3422)US 104784394.7y
Jun 3, 2031method-of-use (U-1684)US 104784394.7y
Jun 3, 2031method-of-use (U-3422)US 104784394.7y
Jun 3, 2031method-of-use (U-1456)US 106536964.7y
Jun 3, 2031method-of-use (U-2943)US 107513424.7y
Jun 3, 2031method-of-use (U-1491)US 107513424.7y
Jun 3, 2031method-of-use (U-2943)US 107513424.7y
Jun 3, 2031method-of-use (U-2943)US 107513424.7y
Jun 3, 2031method-of-use (U-2943)US 107513424.7y
Jun 3, 2031method-of-use (U-1491)US 107513424.7y
Jun 3, 2031method-of-use (U-3842)US 107513424.7y
Jun 3, 2031method-of-use (U-2242)US 116728034.7y
Jun 3, 2031method-of-use (U-1946)US 116728034.7y
Jun 3, 2031method-of-use (U-2242)US 116728034.7y
Jun 3, 2031method-of-use (U-1684)US 116728034.7y
Jun 3, 2031method-of-use (U-2242)US 116728034.7y
Jun 3, 2031method-of-use (U-3843)US 116728034.7y
Jun 3, 2031method-of-use (U-1456)US 87540904.7y
Jun 3, 2031method-of-use (U-1491)US 89999994.7y
Jun 3, 2031method-of-use (U-1946)US 89999994.7y
Jun 3, 2031method-of-use (U-1946)US 89999994.7y
Jun 3, 2031method-of-use (U-3844)US 89999994.7y
Jun 3, 2031method-of-use (U-1946)US 89999994.7y
Jun 3, 2031method-of-use (U-2242)US 89999994.7y
Jun 3, 2031method-of-use (U-1683)US 89999994.7y
Jun 3, 2031method-of-use (U-1650)US 91258894.7y
Jun 3, 2031method-of-use (U-3845)US 91258894.7y
Jun 3, 2031method-of-use (U-1745)US 91258894.7y
Jun 3, 2031method-of-use (U-1650)US 91258894.7y
Jun 3, 2031method-of-use (U-1650)US 91258894.7y
Jun 3, 2031method-of-use (U-1650)US 91258894.7y
Jun 3, 2031method-of-use (U-1650)US 91258894.7y
Jun 3, 2031method-of-use (U-3847)US 98018814.7y
Jun 3, 2031method-of-use (U-2242)US 98018814.7y
Jun 3, 2031method-of-use (U-2242)US 98018814.7y
Jun 3, 2031method-of-use (U-1491)US 98018814.7y
Jun 3, 2031method-of-use (U-2242)US 98018814.7y
Jun 3, 2031method-of-use (U-1491)US 98018814.7y
Jun 3, 2031method-of-use (U-1491)US 98018814.7y
Jun 3, 2031method-of-use (U-2243)US 98018834.7y
Jun 3, 2031method-of-use (U-2159)US 98018834.7y
Jun 3, 2031method-of-use (U-2159)US 98018834.7y
Jun 3, 2031method-of-use (U-2159)US 98018834.7y
Jun 3, 2031method-of-use (U-3844)US 98018834.7y
Jun 3, 2031method-of-use (U-2243)US 98018834.7y
Jun 3, 2031method-of-use (U-2159)US 98018834.7y
Jun 3, 2031method-of-use (U-1947)US 98147214.7y
May 13, 2028patentUS 8008309*PED1.6y
May 13, 2028patentUS 8008309*PED1.6y
May 13, 2028patentUS 8008309*PED1.6y
May 13, 2028patentUS 8008309*PED1.6y
May 13, 2028patentUS 8008309*PED1.6y
May 13, 2028patentUS 8008309*PED1.6y
May 13, 2028patentUS 8008309*PED1.6y
Nov 13, 2027compositionUS 80083091.1y
Nov 13, 2027compositionUS 80083091.1y
Nov 13, 2027compositionUS 80083091.1y
Nov 13, 2027compositionUS 80083091.1y
Nov 13, 2027compositionUS 80083091.1y
Nov 13, 2027compositionUS 80083091.1y
Nov 13, 2027compositionUS 80083091.1y
Oct 26, 2027patentUS 8563563*PED1.1y
Oct 26, 2027patentUS 8563563*PED1.1y
Oct 26, 2027patentUS 8563563*PED1.1y
Oct 26, 2027patentUS 8563563*PED1.1y
Oct 26, 2027patentUS 8563563*PED1.1y
Oct 26, 2027patentUS 8563563*PED1.1y
Jun 28, 2027patentUS 7514444*PED272d
Jun 28, 2027patentUS 7514444*PED272d
Jun 28, 2027patentUS 7514444*PED272d
Jun 28, 2027patentUS 7514444*PED272d
Jun 28, 2027patentUS 7514444*PED272d
Jun 28, 2027patentUS 7514444*PED272d
Jun 28, 2027patentUS 7514444*PED272d
Jun 28, 2027patentUS 8476284*PED272d
Jun 28, 2027patentUS 8476284*PED272d
Jun 28, 2027patentUS 8476284*PED272d
Jun 28, 2027patentUS 8476284*PED272d
Jun 28, 2027patentUS 8476284*PED272d
Jun 28, 2027patentUS 8476284*PED272d
Jun 28, 2027patentUS 8497277*PED272d
Jun 28, 2027patentUS 8497277*PED272d
Jun 28, 2027patentUS 8497277*PED272d
Jun 28, 2027patentUS 8497277*PED272d
Jun 28, 2027patentUS 8497277*PED272d
Jun 28, 2027patentUS 8497277*PED272d
Jun 28, 2027patentUS 8497277*PED272d
Jun 28, 2027patentUS 8697711*PED272d
Jun 28, 2027patentUS 8697711*PED272d
Jun 28, 2027patentUS 8697711*PED272d
Jun 28, 2027patentUS 8697711*PED272d
Jun 28, 2027patentUS 8697711*PED272d
Jun 28, 2027patentUS 8697711*PED272d
Jun 28, 2027patentUS 8697711*PED272d
Jun 28, 2027patentUS 8703780*PED272d
Jun 28, 2027patentUS 8703780*PED272d
Jun 28, 2027patentUS 8703780*PED272d
Jun 28, 2027patentUS 8703780*PED272d
Jun 28, 2027patentUS 8703780*PED272d
Jun 28, 2027patentUS 8703780*PED272d
Jun 28, 2027patentUS 8735403*PED272d
Jun 28, 2027patentUS 8735403*PED272d
Jun 28, 2027patentUS 8735403*PED272d
Jun 28, 2027patentUS 8735403*PED272d
Jun 28, 2027patentUS 8735403*PED272d
Jun 28, 2027patentUS 8735403*PED272d
Jun 28, 2027patentUS 8735403*PED272d
Jun 28, 2027patentUS 8754091*PED272d
Jun 28, 2027patentUS 8754091*PED272d
Jun 28, 2027patentUS 8754091*PED272d
Jun 28, 2027patentUS 8754091*PED272d
Jun 28, 2027patentUS 8754091*PED272d
Jun 28, 2027patentUS 8754091*PED272d
Jun 28, 2027patentUS 8754091*PED272d
Jun 28, 2027patentUS 8952015*PED272d
Jun 28, 2027patentUS 8952015*PED272d
Jun 28, 2027patentUS 8952015*PED272d
Jun 28, 2027patentUS 8952015*PED272d
Jun 28, 2027patentUS 8952015*PED272d
Jun 28, 2027patentUS 8952015*PED272d
Jun 28, 2027patentUS 8957079*PED272d
Jun 28, 2027patentUS 8957079*PED272d
Jun 28, 2027patentUS 8957079*PED272d
Jun 28, 2027patentUS 8957079*PED272d
Jun 28, 2027patentUS 8957079*PED272d
Jun 28, 2027patentUS 8957079*PED272d
Jun 28, 2027patentUS 8957079*PED272d
Jun 28, 2027patentUS 9181257*PED272d
Jun 28, 2027patentUS 9181257*PED272d
Jun 28, 2027patentUS 9181257*PED272d
Jun 28, 2027patentUS 9181257*PED272d
Jun 28, 2027patentUS 9181257*PED272d
Jun 28, 2027patentUS 9181257*PED272d
Jun 28, 2027patentUS 9181257*PED272d
Apr 26, 2027method-of-use (U-1491)US 8563563209d
Apr 26, 2027method-of-use (U-1491)US 8563563209d
Apr 26, 2027method-of-use (U-2241)US 8563563209d
Apr 26, 2027method-of-use (U-3845)US 8563563209d
Apr 26, 2027method-of-use (U-1491)US 8563563209d
Apr 26, 2027method-of-use (U-2242)US 8563563209d
Apr 26, 2027method-of-use (U-1491)US 8563563209d
Dec 28, 2026compositionUS 751444490d
Dec 28, 2026compositionUS 751444490d
Dec 28, 2026compositionUS 751444490d
Dec 28, 2026compositionUS 751444490d
Dec 28, 2026compositionUS 751444490d
Dec 28, 2026compositionUS 751444490d
Dec 28, 2026compositionUS 751444490d
Dec 28, 2026method-of-use (U-1650)US 847628490d
Dec 28, 2026method-of-use (U-3845)US 847628490d
Dec 28, 2026method-of-use (U-1946)US 847628490d
Dec 28, 2026method-of-use (U-2241)US 847628490d
Dec 28, 2026method-of-use (U-2241)US 847628490d
Dec 28, 2026method-of-use (U-1946)US 847628490d
Dec 28, 2026method-of-use (U-1650)US 847628490d
Dec 28, 2026method-of-use (U-1650)US 849727790d
Dec 28, 2026method-of-use (U-2242)US 849727790d
Dec 28, 2026method-of-use (U-3422)US 849727790d
Dec 28, 2026method-of-use (U-2970)US 849727790d
Dec 28, 2026method-of-use (U-1491)US 849727790d
Dec 28, 2026method-of-use (U-3422)US 849727790d
Dec 28, 2026method-of-use (U-1456)US 849727790d
Dec 28, 2026compositionUS 869771190d
Dec 28, 2026compositionUS 869771190d
Dec 28, 2026compositionUS 869771190d
Dec 28, 2026compositionUS 869771190d
Dec 28, 2026compositionUS 869771190d
Dec 28, 2026compositionUS 869771190d
Dec 28, 2026compositionUS 869771190d
Dec 28, 2026method-of-use (U-3842)US 870378090d
Dec 28, 2026method-of-use (U-2242)US 870378090d
Dec 28, 2026method-of-use (U-2242)US 870378090d
Dec 28, 2026method-of-use (U-1491)US 870378090d
Dec 28, 2026method-of-use (U-1491)US 870378090d
Dec 28, 2026method-of-use (U-2242)US 870378090d
Dec 28, 2026method-of-use (U-1491)US 870378090d
Dec 28, 2026compositionUS 873540390d
Dec 28, 2026compositionUS 873540390d
Dec 28, 2026compositionUS 873540390d
Dec 28, 2026compositionUS 873540390d
Dec 28, 2026compositionUS 873540390d
Dec 28, 2026compositionUS 873540390d
Dec 28, 2026compositionUS 873540390d
Dec 28, 2026formulationUS 875409190d
Dec 28, 2026formulationUS 875409190d
Dec 28, 2026formulationUS 875409190d
Dec 28, 2026formulationUS 875409190d
Dec 28, 2026formulationUS 875409190d
Dec 28, 2026formulationUS 875409190d
Dec 28, 2026formulationUS 875409190d
Dec 28, 2026method-of-use (U-1946)US 895201590d
Dec 28, 2026method-of-use (U-2241)US 895201590d
Dec 28, 2026method-of-use (U-1491)US 895201590d
Dec 28, 2026method-of-use (U-1946)US 895201590d
Dec 28, 2026method-of-use (U-1491)US 895201590d
Dec 28, 2026method-of-use (U-3845)US 895201590d
Dec 28, 2026method-of-use (U-1946)US 895201590d
Dec 28, 2026compositionUS 895707990d
Dec 28, 2026compositionUS 895707990d
Dec 28, 2026compositionUS 895707990d
Dec 28, 2026compositionUS 895707990d
Dec 28, 2026compositionUS 895707990d
Dec 28, 2026compositionUS 895707990d
Dec 28, 2026compositionUS 895707990d
Dec 28, 2026compositionUS 918125790d
Dec 28, 2026compositionUS 918125790d
Dec 28, 2026compositionUS 918125790d
Dec 28, 2026compositionUS 918125790d
Dec 28, 2026compositionUS 918125790d
Dec 28, 2026compositionUS 918125790d
Dec 28, 2026compositionUS 918125790d

FDA exclusivities (28)

Feb 24, 2030PEDPediatric (6mo bonus)3.4y
Feb 24, 2030PEDPediatric (6mo bonus)3.4y
Feb 24, 2030PEDPediatric (6mo bonus)3.4y
Feb 24, 2030PEDPediatric (6mo bonus)3.4y
Feb 24, 2030PEDPediatric (6mo bonus)3.4y
Feb 24, 2030PEDPediatric (6mo bonus)3.4y
Feb 24, 2030PEDPediatric (6mo bonus)3.4y
Aug 24, 2029ODE-405Orphan Drug (7y)2.9y
Aug 24, 2029ODE-405Orphan Drug (7y)2.9y
Aug 24, 2029ODE-405Orphan Drug (7y)2.9y
Aug 24, 2029ODE-405Orphan Drug (7y)2.9y
Aug 24, 2029ODE-405Orphan Drug (7y)2.9y
Aug 24, 2029ODE-405Orphan Drug (7y)2.9y
Aug 24, 2029ODE-405Orphan Drug (7y)2.9y
Feb 24, 2026PEDPediatric (6mo bonus)
Feb 24, 2026PEDPediatric (6mo bonus)
Feb 24, 2026PEDPediatric (6mo bonus)
Feb 24, 2026PEDPediatric (6mo bonus)
Feb 24, 2026PEDPediatric (6mo bonus)
Feb 24, 2026PEDPediatric (6mo bonus)
Feb 24, 2026PEDPediatric (6mo bonus)
Aug 24, 2025NPPNew Product (3y)
Aug 24, 2025NPNP
Aug 24, 2025NPPNew Product (3y)
Aug 24, 2025NPPNew Product (3y)
Aug 24, 2025NPPNew Product (3y)
Aug 24, 2025NPPNew Product (3y)
Aug 24, 2025NPPNew Product (3y)

News(3)

J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.
biopharma_dive · 2mo ago
Ibrutinib Monotherapy Yields Decade-Long Durable Efficacy in Across CLL Subtypes
Ibrutinib monotherapy produced durable efficacy over 10 years in patients with or without TP53-mutated chronic lymphocytic leukemia.
onclive · 4mo ago
Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL
Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.
onclive · 4mo ago

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 7m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(3)

J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals

J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.

biopharma_dive · 2mo ago

Ibrutinib Monotherapy Yields Decade-Long Durable Efficacy in Across CLL Subtypes

Ibrutinib monotherapy produced durable efficacy over 10 years in patients with or without TP53-mutated chronic lymphocytic leukemia.

onclive · 4mo ago

Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL

Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.

onclive · 4mo ago

ibrutinib

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying ibrutinib

Patent cliff

patents (448)

FDA exclusivities (28)

News(3)

Report a data issue

comments(0)

ibrutinib

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying ibrutinib

Patent cliff

patents (448)

FDA exclusivities (28)

News(3)

Report a data issue

comments(0)